157 related articles for article (PubMed ID: 38089085)
1. Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma.
Guo L; Huai Q; Zhou B; Ying J; Guo W
Cancer Innov; 2022 Dec; 1(4):328-343. PubMed ID: 38089085
[TBL] [Abstract][Full Text] [Related]
2. Gene amplification-driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A-YTHDF2-dependent in lung adenocarcinoma.
Zhang C; Sun Q; Zhang X; Qin N; Pu Z; Gu Y; Yan C; Zhu M; Dai J; Wang C; Li N; Jin G; Ma H; Hu Z; Zhang E; Tan F; Shen H
Cancer Commun (Lond); 2022 Jul; 42(7):609-626. PubMed ID: 35730068
[TBL] [Abstract][Full Text] [Related]
3. KIAA1429 promotes the progression of lung adenocarcinoma by regulating the m6A level of MUC3A.
Zhao W; Xie Y
Pathol Res Pract; 2021 Jan; 217():153284. PubMed ID: 33249400
[TBL] [Abstract][Full Text] [Related]
4. Expression and Prognostic Significance of m6A-Related Genes in Lung Adenocarcinoma.
Zhang Y; Liu X; Liu L; Li J; Hu Q; Sun R
Med Sci Monit; 2020 Feb; 26():e919644. PubMed ID: 32086933
[TBL] [Abstract][Full Text] [Related]
5. KIAA1429 regulates lung adenocarcinoma proliferation and metastasis through the PI3K/AKT pathway by modulating ARHGAP30 expression.
Guo W; Wang T; Huai Q; Guo L; Wang X; He J
Thorac Cancer; 2024 Jun; 15(18):1397-1409. PubMed ID: 38717936
[TBL] [Abstract][Full Text] [Related]
6. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
[TBL] [Abstract][Full Text] [Related]
7. KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m
Lin X; Ye R; Li Z; Zhang B; Huang Y; Du J; Wang B; Meng H; Xian H; Yang X; Zhang X; Zhong Y; Huang Z
Drug Resist Updat; 2023 Jan; 66():100908. PubMed ID: 36493511
[TBL] [Abstract][Full Text] [Related]
8. Pan-cancer analysis and experimental validation revealed the m6A methyltransferase KIAA1429 as a potential biomarker for diagnosis, prognosis, and immunotherapy.
Ma C; Zheng Q; Wang Y; Li G; Zhao M; Sun Z
Aging (Albany NY); 2023 Aug; 15(17):8664-8691. PubMed ID: 37606975
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
10. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
Wang Z; Wang C; Lin S; Yu X
Front Oncol; 2021; 11():725292. PubMed ID: 34513703
[TBL] [Abstract][Full Text] [Related]
11. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
12. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3.
Lan T; Li H; Zhang D; Xu L; Liu H; Hao X; Yan X; Liao H; Chen X; Xie K; Li J; Liao M; Huang J; Yuan K; Zeng Y; Wu H
Mol Cancer; 2019 Dec; 18(1):186. PubMed ID: 31856849
[TBL] [Abstract][Full Text] [Related]
13. RNA-Binding Protein IGF2BP1 Associated With Prognosis and Immunotherapy Response in Lung Adenocarcinoma.
Liu J; Li Z; Cheang I; Li J; Zhou C
Front Genet; 2022; 13():777399. PubMed ID: 35154270
[TBL] [Abstract][Full Text] [Related]
14. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
Zhao J; Lin X; Zhuang J; He F
Front Genet; 2021; 12():714697. PubMed ID: 34777460
[No Abstract] [Full Text] [Related]
15. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
16. [Comprehensive Analysis of the Relationship between m6A Methylation Patterns and Immune Microenvironment in Lung Adenocarcinoma].
Ke J; Cui J; Yang X; Du X; Ma B; Yu L
Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):311-322. PubMed ID: 35599007
[TBL] [Abstract][Full Text] [Related]
17. Elevated Heterogeneous Nuclear Ribonucleoprotein C Expression Correlates With Poor Prognosis in Patients With Surgically Resected Lung Adenocarcinoma.
Guo W; Huai Q; Zhang G; Guo L; Song P; Xue X; Tan F; Xue Q; Gao S; He J
Front Oncol; 2020; 10():598437. PubMed ID: 33569346
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma.
Tian L; Wang Y; Tian J; Song W; Li L; Che G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analyses of one-carbon metabolism related genes and their association with prognosis, tumor microenvironment, chemotherapy resistance and immunotherapy in lung adenocarcinoma.
Zhou N; Tang Q; Yu H; Li T; Ren F; Zu L; Chen G; Chen J; Xu S
Front Mol Biosci; 2022; 9():1034208. PubMed ID: 36438661
[No Abstract] [Full Text] [Related]
20. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Ma Y; Yang J; Ji T; Wen F
Front Genet; 2022; 13():990623. PubMed ID: 36246622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
